SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
Customer Cash Receipts (A$’000) Customer Cash Receipts (A$’000) MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE)…
Customer Cash Receipts (A$’000) Customer Cash Receipts (A$’000) MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE)…
CLEVELAND, July 28, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that…
CLEVELAND, July 28, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that…
The MyMedi.ca medical cannabis care platform is preparing to launch August 1, 2023 The new…
The MyMedi.ca medical cannabis care platform is preparing to launch August 1, 2023 The new…
Online availability of Sanofi’s half-year financial report for 2023 Paris, July 28, 2023. Sanofi announces…
Online availability of Sanofi’s half-year financial report for 2023 Paris, July 28, 2023. Sanofi announces…
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN…
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN…
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia …
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia …
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center,…
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center,…
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28,…
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28,…
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1…
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1…